The Oncology Institute Posts Strong Q1 2026 Revenue Growth, Narrows Losses
Event summary
- The Oncology Institute reported Q1 2026 revenue of $147.4M, up 41.2% YoY, driven by specialty pharmacy growth and Medicare Advantage expansion.
- Net loss narrowed to $2.5M from $19.6M in the prior-year quarter, with adjusted EBITDA improving to $(2.4)M from $(5.1)M.
- Specialty Pharmacy revenue surged 78% YoY, while Medicare Advantage lives grew to 200,000 across 25 Florida counties.
- TOI saved $2M in Medicare spending under the CMS Enhancing Oncology Model, maintaining high-quality care.
- The company reaffirmed 2026 revenue guidance of $630M–$650M and upgraded free cash flow outlook to $5M–$15M.
The big picture
TOI's Q1 2026 results highlight the scalability of its value-based oncology model, particularly in Florida. The company's ability to narrow losses while expanding Medicare Advantage lives and specialty pharmacy revenue reflects broader industry shifts toward capitated payment models. However, sustaining profitability will depend on maintaining cost efficiencies and clinical pathway adherence across its growing network.
What we're watching
- Execution Risk
- Whether TOI can sustain its Florida profitability and specialty pharmacy growth amid seasonal fluctuations.
- Regulatory Dynamics
- How CMS model performance and Medicare Advantage expansion will impact long-term margins.
- Market Positioning
- The pace at which TOI can scale its provider portal to strengthen network physician adherence.
Related topics